Toward gene therapy for congenital thrombotic thrombocytopenic purpura

Area of Science:

• Hematology
• Genetics
• Pharmacology

Background:

• Congenital thrombotic thrombocytopenic purpura (cTTP) results from severe ADAMTS-13 deficiency.
• Current treatments involve lifelong plasma infusions of ADAMTS-13, which are burdensome and have side effects.
• Existing therapies manage acute episodes but do not offer a cure for cTTP.

Purpose of the Study:

• To review preclinical gene therapy approaches for cTTP.
• To discuss challenges in developing gene therapy for cTTP.

Main Methods:

• Literature review of preclinical gene therapy studies for cTTP.

Main Results:

• Gene therapy aims to achieve endogenous ADAMTS-13 expression for a curative effect.
• Various preclinical gene therapeutic strategies are under investigation for cTTP.

Conclusions:

• Gene therapy holds promise for a curative treatment for cTTP.
• Overcoming challenges in developing gene therapy medicinal products is crucial for clinical application.